LadRx and ImmunityBio Terminate Aldoxorubicin License Agreement
Monday, 3 June 2024, 20:56
LadRx and ImmunityBio Reach Mutual Agreement
The recent announcement reveals that LadRx and ImmunityBio have mutually decided to terminate the Aldoxorubicin license. This move comes as a strategic decision that could impact their future collaborations and research endeavors.
Implications for Aldoxorubicin Development
In a bold move, both companies are now facing the consequences of ending this agreement, potentially leading to new opportunities or challenges in the pharmaceutical sector.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.